Cargando…

Midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension treated with treprostinil

BACKGROUND: To investigate the midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension (PAH) using subcutaneous injection of treprostinil. METHODS: A retrospective study was conducted on 61 patients with severe left...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Ning, Huang, Shu-Ting, Sun, Kai-Peng, Wang, Zeng-Chun, Cao, Hua, Chen, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641841/ https://www.ncbi.nlm.nih.gov/pubmed/33143649 http://dx.doi.org/10.1186/s12872-020-01759-9

Ejemplares similares

Effect of Treprostinil on the Early Postoperative Prognosis of Patients with Severe Left Heart Valvular Disease Combined with Severe Pulmonary Hypertension
por: Huang, Shu-Ting, et al.
Publicado: (2020)

Treprostinil for pulmonary hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2008)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
por: Furukawa, Asuka, et al.
Publicado: (2017)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Inhaled treprostinil and pulmonary arterial hypertension
por: Nadler, Samuel T, et al.
Publicado: (2010)

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil
por: Jansa, Pavel, et al.
Publicado: (2023)

The Rapid Initiation, Titration, and Transition from Intravenous to Oral Treprostinil in a Patient with Severe Pulmonary Arterial Hypertension
por: Gleason, James Benjamin, et al.
Publicado: (2015)

Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension
por: Khan, Akram, et al.
Publicado: (2022)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2018)

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
por: Desole, Susanna, et al.
Publicado: (2018)

Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
por: Ivy, D. Dunbar, et al.
Publicado: (2019)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
por: McSweeney, Julia, et al.
Publicado: (2023)

The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease
por: Bajwa, Abubakr A., et al.
Publicado: (2017)

Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
por: Mirza, Shireen, et al.
Publicado: (2012)

Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review
por: Buckley, Mitchell S, et al.
Publicado: (2014)

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
por: Pugliese, Steven C, et al.
Publicado: (2016)

An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
por: Kurzyna, Marcin, et al.
Publicado: (2017)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
por: Oriaku, Ifeoma, et al.
Publicado: (2020)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
por: Kuwana, Masataka, et al.
Publicado: (2023)

Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina
por: Lescano, Adrián, et al.
Publicado: (2022)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
por: Chapman, Richard W., et al.
Publicado: (2021)

8% Capsaicin Patch as Analgesia for Severe Treprostinil Infusion Site Pain
por: Light, Allison, et al.
Publicado: (2017)

Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension
por: Smadja, David M., et al.
Publicado: (2010)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
por: Swisher, John W., et al.
Publicado: (2016)

Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience
por: Coons, James C., et al.
Publicado: (2018)

Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
por: Plaunt, Adam J., et al.
Publicado: (2021)

Inhaled Treprostinil in Pulmonary Hypertension in the Context of Interstitial Lung Disease: A Success, Finally
por: Behr, Jürgen
Publicado: (2021)

Prenatal treprostinil reduces the pulmonary hypertension phenotype in the rat model of congenital diaphragmatic hernia
por: De Bie, Felix Rafael, et al.
Publicado: (2022)

Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases
por: Kavgacı, Akif, et al.
Publicado: (2023)

Intravenous Treprostinil in Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension Using Implantable Pumps—Single-Center Experience over More Than a Decade
por: Steringer-Mascherbauer, Regina, et al.
Publicado: (2023)

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
por: Richter, Manuel J., et al.
Publicado: (2020)

Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics
por: White, R. James, et al.
Publicado: (2020)

A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil
por: Zwicke, Diane L., et al.
Publicado: (2021)

A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension
por: Coons, James C., et al.
Publicado: (2021)

Patient Satisfaction with a Dedicated Infusion Pump for Subcutaneous Treprostinil to Treat Pulmonary Arterial Hypertension
por: Waligóra, Marcin, et al.
Publicado: (2023)

Clinical profile and midterm prognosis of left ventricular thrombus in heart failure
por: Lemaître, Anne‐Iris, et al.
Publicado: (2021)

Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension
por: Chen, Hubert, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_l4prfsp4rvl1v0pq9aksngs44v